Wild-Type CXCR3 | His III:05 (His128)-CXCR3 | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Log EC50 | EC50 | n | Emax | Log EC50 | EC50 | n | Finc | Emax | Emax | |||||||||
nM | fmol/105 cells | nM | -fold | fmol / 105 cells | % | |||||||||||||
Endogenous chemokines | ||||||||||||||||||
ITAC (CXCL11) | -8.8 ± 0.08 | 1.7 | 23 | 544 ± 67 | -7.8 ± 0.09 | 15 | 16 | 0.11 | 215 ± 31 | 100 | ||||||||
IP10 (CXCL10) | -8.0 ± 0.10 | 11 | 21 | 407 ± 46 | -6.9 ± 0.22 | 163 | 14 | 0.07 | 163 ± 32 | 72 | ||||||||
Metal ion chelator complexes | ||||||||||||||||||
Cu(II)-Bip | -3.0 ± 0.09 | 973a | 19 | NE | -4.7 ± 0.11 | 22 | 18 | 44 | 347 ± 32 | 171 | ||||||||
Zn(II)-Bip | -2.9 ± 0.01 | 1169a | 9 | NE | -4.3 ± 0.08 | 53 | 15 | 22 | 313 ± 33 | 153 | ||||||||
Cu(II)-Phen | -3.5 ± 0.12 | 302a | 8 | NE | -5.1 ± 0.04 | 8.0 | 10 | 38 | 327 ± 60 | 161 | ||||||||
Zn(II)-Phen | -3.2 ± 0.18 | 595a | 6 | NE | -4.7 ± 0.05 | 21 | 8 | 29 | 300 ± 53 | 146 | ||||||||
Metal ions | ||||||||||||||||||
Cu (II) | <-2 | >10,000 | 4 | NE | <-2 | >10,000 | 6 | NE | NE | |||||||||
Zn (II) | <-2 | >10,000 | 4 | NE | <-2 | >10,000 | 6 |
| NE | NE |
Emax, maximum stimulation; Finc, -fold increase in potency for each ligand on His III:05-CXCR3 compared with wild-type CXCR3; Emax (%), average specific efficacy of a given ligand where 100% equals the maximal specific ITAC stimulation on His III:05-CXCR3; Bip, bipyridine; Phen, phenanthrolene; NE, no detectable Emax.
↵ a The EC50 was estimated by a nonlinear regression using the sigmoidal dose-response algorithm in GraphPad Prism with a constant Hill coefficient of 1.5 corresponding to the Hill coefficient of the metal ion chelator complexes on His III:05 CXCR3.